Article
NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.
Proceedings of the National Academy of Sciences of the United States of America - 3 May 2016
Chiu Ching-Feng, Chang Yi-Wen, Kuo Kuang-Tai, Shen Yu-Shiuan, Liu Chien-Ying, Yu Yang-Hao, Cheng Ching-Chia, Lee Kang-Yun, Chen Feng-Chi, Hsu Min-Kung, Kuo Tsang-Chih, Ma Jui-Ti, Su Jen-Liang
Abstract excerpt
Therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs, such as gefitinib or erlotinib) significantly prolongs survival time for patients with tumors harboring an activated mutation on EGFR; however, up to 40% of lung cancer patients exhibit acquired resistance to EGFR-TKIs with an unknown mechanism. FOXO3a, a transcription factor of the forkhead family, triggers apoptosis, but...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.